Anthem (ANTM) PT Raised to $361 at UBS, Long-term & 2022 Earnings Potential Stays unchanged
- Wall Street gains evaporate, S&P 500 ends lower on Fed tightening timeline
- Tesla (TSLA) Reports Strong Q4 Beat, Achieves Record Vehicle Deliveries in 2021
- Intel (INTC) Reports Q4 Beat, Shares Down 2% on Guidance Miss
- Fed maintains federal funds rate at 0 to 1/4 percent, reduces assets purchases by another $30 billion/month and sees ending them in March
- Ackman Says Pershing Square Bought Over 3.1M Shares of Netflix (NFLX)
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
UBS analyst Whit Mayo raised the price target on Anthem (NYSE: ANTM) to $361.00 (from $335.00) while maintaining a Buy rating.
The analyst comments "ANTM posted in-line results with well controlled medical costs (MLR 88.9% vs cons of 90%) providing a modest amount of upside offset by higher SG&A (13.7% vs cons of 12.9%). ANTM gave an updated view on 2021 guiding EPS 3.4% below cons and MLR 100bps higher. Mgmt cited a $0.50-$0.70 headwind to MA. UNH and HUM cited similar headwinds and we see ANTM's guidance posture as conservative. ANTM continues to grow its risk book with both resiliency in its commercial membership and outsized gains in its MA and MDCD membership. ANTM remains on track to grow its MA business middouble digits in 2021 and expects to reach 10m Medicaid members in 2021. The outyear growth prospects remain unchanged w/ mgmt reiterating its long-term EPS growth target of 12-15% and blessing $25.10 as a good jumping off point pinning 2022 in the zone of current consensus. Buy."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla (TSLA) PT Raised to $1,300 at CFRA
- United Microelectronics Corp (2303:TT) (UMC) PT Lowered to NT$66 at JPMorgan
- Musashi Seimitsu Industry Co Ltd (7220:JP) PT Lowered to JPY2,500 at Credit Suisse
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change
Related EntitiesUBS, Earnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!